Analyzing Entero Therapeutics (ENTO) & Its Peers

Entero Therapeutics (NASDAQ:ENTO) is one of 618 publicly-traded companies in the “MED – BIOMED/GENE” industry, but how does it compare to its peers? We will compare Entero Therapeutics to similar companies based on the strength of its analyst recommendations, dividends, profitability, risk, institutional ownership, earnings and valuation.

Valuation and Earnings

This table compares Entero Therapeutics and its peers gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Entero Therapeutics	N/A	-$18.06 million	-1.72
Entero Therapeutics Competitors	$971.71 million	-$43.64 million	14.82

Entero Therapeutics’ peers have higher revenue, but lower earnings than Entero Therapeutics. Entero Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Insider and Institutional Ownership

12.3% of Entero Therapeutics shares are owned by institutional investors. Comparatively, 51.2% of shares of all “MED – BIOMED/GENE” companies are owned by institutional investors. 0.8% of Entero Therapeutics shares are owned by company insiders. Comparatively, 13.6% of shares of all “MED – BIOMED/GENE” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Entero Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Entero Therapeutics	N/A	-1,063.82%	-17.94%
Entero Therapeutics Competitors	-1,412.64%	-642.51%	-28.22%

Volatility & Risk

Entero Therapeutics has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500. Comparatively, Entero Therapeutics’ peers have a beta of 0.97, indicating that their average share price is 3% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for Entero Therapeutics and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entero Therapeutics	1	0	0	0	1.00
Entero Therapeutics Competitors	5311	11904	37071	1116	2.61

As a group, “MED – BIOMED/GENE” companies have a potential upside of 66.16%. Given Entero Therapeutics’ peers stronger consensus rating and higher probable upside, analysts clearly believe Entero Therapeutics has less favorable growth aspects than its peers.

Summary

Entero Therapeutics peers beat Entero Therapeutics on 9 of the 13 factors compared.

Entero Therapeutics Company Profile

Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis. It is also involved in the development of adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, currently under Phase 2 studies for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis; and niclosamide, an oral small molecule with anti-inflammatory inhibitor therapy, currently under Phase 2 studies for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis, as well as immune checkpoint inhibitor-associated colitis and diarrhea in metastatic cancer patients. The company was formerly known as First Wave BioPharma, Inc. and changed its name to Entero Therapeutics, Inc. in May 2024. Entero Therapeutics, Inc. was incorporated in 2014 and is based in Boca Raton, Florida.